Effect of CC-5013, rapamycin, and combination on patient myeloma cells. A dose-dependent increase in the percentage of apoptotic patient MM cells, evidenced by Apo 2.7 staining of bright CD38-positive cells, was noted after exposure to combination CC-5013 and rapamycin treatment.